Goldman Sachs
CRL icon

Goldman Sachs’s Charles River Laboratories CRL Stock Holding History

Goldman Sachs’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,700
Closed -$243K – 6783
2017
Q1 		$243K Buy
+2,700
New +$229K ﹤0.01% 5598
2013
Q3 		– Sell
-50,000
Closed -$2.05M – 6572
2013
Q2 		$2.05M Buy
+50,000
New +$2.14M ﹤0.01% 3706

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Goldman Sachs's CRL Position: Q2 2026 in Review

Goldman Sachs increased its Charles River Laboratories (CRL) stake by 54% in Q2 2026, buying an estimated $40.1M and bringing the position to 639,803 shares worth $145M. The position accounts for 0.01% of the portfolio, ranked #952.

Goldman Sachs first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $150M in Q1 2025. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Goldman Sachs held 639,803 shares of Charles River Laboratories worth $145M as of Q2 2026.
  • Goldman Sachs bought 225,075 Charles River Laboratories shares in Q2 2026, an estimated $40.1M.
  • Charles River Laboratories made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #952 holding.
  • Goldman Sachs first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
  • Goldman Sachs's Charles River Laboratories position peaked at $150M in Q1 2025.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.